CARDIOL THERAPEUTICS
Commented by Stefan Feulner on September 20th, 2021 | 12:05 CEST
Valneva, Cardiol Therapeutics, BioNTech - Recurring businesses
The vaccination rate is stalling. Around 4 million out of 24 million people over the age of 60 are still unvaccinated. Politicians led by Health Minister Jens Spahn have now launched a vaccination campaign week to get more people immunized against the coronavirus. The proportion of vaccinated people in Germany is still too low to prevent a new Corona wave and a possible resulting overload of the healthcare system. Meanwhile, vaccine producers are already working on the approval of booster shots. Profits should continue to bubble up for a long time.
Read
Commented by Nico Popp on September 15th, 2021 | 12:17 CEST
Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase
The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.
Read
Commented by Nico Popp on August 26th, 2021 | 10:41 CEST
BioNTech, Cardiol Therapeutics, Bayer: Where Covid-19 still provides returns
The pandemic has not only brought losers. There is also a long list of winners. Starting with Amazon and Deutsche Post and ending with BioNTech. Before Corona, the latter Company was always considered a beacon of hope around mRNA technology. Then came the pandemic, and suddenly several small test balloons turned into a gigantic project as we know it today, with a successful outcome. We shed light on BioNTech and also focus on other potential winners of the pandemic.
Read
Commented by André Will-Laudien on August 18th, 2021 | 10:43 CEST
Bayer, Cardiol Therapeutics, CureVac: The Champions League of Bio-Pharma!
Biopharmaceutics is the first port of call in the fight against a wide range of diseases. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. Biological effectiveness results from the entry of the drug into the diseased organism, its distribution in tissues, and the chemical reaction called metabolism. When dealing with recent pandemics, good advice is expensive, and research into pharmaceuticals costs billions. When an active ingredient is found and registered, the patent clock starts ticking for the inventor. As a result, the hope of the biopharmaceutical company is to remain the sole provider in their healing segment for as long as possible.
Read
Commented by Stefan Feulner on August 3rd, 2021 | 12:22 CEST
Siemens Healthineers, Cardiol Therapeutics, BioNTech - Tomorrow's blockbusters
The fight against the coronavirus and the possible return to everyday life promises companies in the biotechnology sector billions in profits. At the forefront, vaccine producers such as BioNTech with its pharmaceutical partner Pfizer or Moderna are the primary beneficiaries of the pandemic. In addition, start-ups are emerging from the diagnostics and therapy sectors, whose formulations have blockbuster potential and could follow a similar path to the vaccine manufacturers in the coming years.
Read
Commented by Carsten Mainitz on July 26th, 2021 | 13:55 CEST
BioNTech, Cardiol Therapeutics, CureVac - What is next?
Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?
Read
Commented by Nico Popp on July 20th, 2021 | 13:42 CEST
Siemens Healthineers, Cardiol Therapeutics, CureVac: Where there is music to be heard by the end of the year
Health is the highest good. Anyone who has ever experienced people having the "plug pulled" on them overnight can undoubtedly relate to this truism. Fortunately, medicine in this country is able to provide a quick remedy. A wide range of options are available for both diagnosis and therapy. In addition to laboratory analyses, imaging procedures also ensure that disease patterns can be narrowed down and, thus, treatments can be carried out in a targeted manner. Although our drugs are already powerful, new, more innovative approaches are emerging all the time. This development is also benefiting investors.
Read
Commented by Armin Schulz on July 14th, 2021 | 10:54 CEST
Cardiol Therapeutics, CureVac, Bayer - Where is the journey heading?
One might think that the pharmaceutical industry is the big winner of the Corona Crisis. However, according to a study by EY, this is not the case. Sales did increase by an average of 4.4% at the largest pharma companies, a much better result than in many other industries, but compared to 2019, growth actually fell by 8.4%. That is due to the postponement of medical treatments due to the Corona Crisis. The industry benefits from the ever-increasing number of elderly people worldwide and, at the same time, the development of new drugs. As a result, sales and profits have increased even during the crisis. We, therefore, highlight three companies from the pharma sector.
Read
Commented by Carsten Mainitz on June 30th, 2021 | 12:59 CEST
CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!
Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?
Read
Commented by Stefan Feulner on June 24th, 2021 | 12:52 CEST
CureVac, Cardiol Therapeutics, Bayer - Where we go from here
Biotechnology has an extraordinary impact on our lives. The perception and appreciation of the future industry of the 21st century has increased significantly in the past year. All thanks due to the race for vaccines against the coronavirus. Yet investing in a biotechnology startup requires patience and a willingness to take risks. The risk that an active ingredient will not work in the end, as the example of CureVac shows, is high. On the other hand, however, investors have the opportunity to multiply their invested capital in the event of successful approval.
Read